Oita IAM

[Not Yet Scheduled]
The company holds capability of designing small molecule compound that target inhibition of protein-protein interaction based on structural information of the protein and the ligand.
The uniqueness of the compound is that it consists of three-dimensional scaffold structure with side chains which amino acid binds to. This creates a three-dimensionally structured compound that mimics structure of the ligand resulting in specific binding to the target protein.
The specificity and the molecule size allow the compound to target intercellular PPI while limiting the off-target effect, which can be essential when targeting intercellular molecules.
Not only can the company design compounds, we also have the capability to synthesize the compound in reasonable number of synthetic steps.
Company Type:
Privately Funded Company
Company Website:
Company HQ State:
Not Provided
Company HQ Country:
Japan
Year Founded:
2017
Main Therapeutic Focus:
Lead Product in Development:
Treatment of rabies virus infection
Development Phase of Primary Product:
Number Of Unlicensed Products (For Which You Are Seeking Partners):
Not Provided
Speaker
photo
Manager
Oita IAM